AstraZeneca
AstraZeneca to pay up to $1.2 billion for Pearl
June 10, 2013Research and Development, Sales and Marketing AstraZeneca, COPD, pearl therapeutics
AstraZeneca is betting big on lung disease specialist Pearl Therapeutics as it looks to spend $1.2 billion to acquire the …
AstraZeneca abandons late-stage RA drug
June 5, 2013Research and Development, Sales and Marketing AstraZeneca, RA, Rigel
AstraZeneca is to exit development of a new rheumatoid arthritis drug, after Phase III trials produced disappointing results.The Anglo-Swedish firm …
AstraZeneca/BMS drug granted speedy FDA review
June 5, 2013Sales and Marketing AstraZeneca, BMS, lipodystrophy
AstraZeneca and partner Bristol-Myers Squibb have been granted a priority review for their rare disease drug metreleptin. The medicine is …
AstraZeneca and CRUK partner on drug trial
May 31, 2013Sales and Marketing AstraZeneca, CRUK
AstraZeneca is partnering with Cancer Research UK to develop a new oncology medicine that targets a number of different cancers. …
AstraZeneca reveals Alderley Park plan
May 8, 2013Research and Development, Sales and Marketing AstraZeneca, BioCity, R&D, alderley
AstraZeneca has left a key question about what to do with its soon-to-be defunct R&D site in Cheshire in the …
AstraZeneca signs $200m nanomedicine deal
April 23, 2013Research and Development, Sales and Marketing AstraZeneca, bind therapeutics, nanomedicine
AstraZeneca has signed an agreement to develop and commercialise a cancer nanomedicine from US firm Bind Therapeutics’ stable of Accurins. …
Oxford Cancer Biomarkers signs discovery deal with AstraZeneca
April 18, 2013Research and Development AstraZeneca, Oxford Cancer Biomarkers
AstraZeneca has signed a new alliance with a UK firm in the field of biomarker discovery.Oxford Cancer Biomarkers is developing …
MedImmune buys AlphaCore
April 9, 2013Research and Development AlphaCore, AstraZeneca, MedImmune
AstraZeneca’s biologics R&D arm MedImmune has bought private US biotech firm AlphaCore Pharma for an undisclosed sum.The acquisition is part …
AstraZeneca settles Crestor case
March 26, 2013Sales and Marketing AstraZeneca, Crestor, Watson
AstraZeneca has settled a long-running legal battle over one of its biggest brands, Crestor, whose patent expires in 2016. The …
AstraZeneca hires strategy boss
March 25, 2013Sales and Marketing AstraZeneca, dunoyer
AstraZeneca has poached one of GlaxoSmithKline’s senior executives to help push through its new growth strategy. Marc Dunoyer, global head …
AstraZeneca sets out growth strategy
March 21, 2013Sales and Marketing AstraZeneca, R&D
AstraZeneca has set out an ambitious plan designed to return it to growth which eschews diversification and sets great store …
AstraZeneca restructures global R&D
March 19, 2013Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, R&D
AstraZeneca is restructuring its global operations in a bid to improve the productivity of its R&D operations. The firm is …
NICE rejects Forxiga
February 1, 2013Sales and Marketing AstraZeneca, BMS, Forxiga, NICE, diabetes
NICE has given the thumbs-down to AstraZeneca and Bristol-Myers Squibb’s first-in-class type II diabetes treatment Forxiga. The drug was approved …
AstraZeneca signs respiratory deal
January 29, 2013Research and Development, Sales and Marketing AstraZeneca, COPD, orexo, respiratory
AstraZeneca has signed a research deal with Swedish pharma company Orexo centred around the development of respiratory disease treatments. For …
AstraZeneca shakes up management
January 16, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Mackay, R&D, Soriot
AstraZeneca has taken its most dramatic steps yet to arrest decline, with chief executive Pascal Soriot axeing two senior positions …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
